13 July 2023
IntegraGen reports €5.6m in revenues for H1 2023 representing 13% decrease compared to H1 2022 and a cash position of €4.3m

Évry, France, Thursday July (…) »
13 July 2023
Évry, France, Thursday July (…) »
24 April 2023
Evry, France, april 24th 2023, 6 pm – IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), IntegraGen, a company specializing in the decryption of the (…) »
13 January 2023
EVRY, FRANCE, FRIDAY JANUARY 13TH 2023, 7.30AM CET – IntegraGen (FR0010908723 – ALINT), an OncoDNA Group company specializing in the decryption of (…) »
18 October 2022
EVRY, FRANCE, TUESDAY OCTOBER 18TH 2022, 7.30AM – IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), IntegraGen, a company specializing in the decryption (…) »
13 July 2022
Evry, France, Wednesday July 13th 2022, 7.30am – IntegraGen (FR0010908723 – ALINT ), an OncoDNA Group company specializing in the decryption of the human genome which performs (…) »
29 April 2022
Évry, France, april 29TH 2022 – 6.00pm (…) »
14 January 2022
EVRY, FRANCE, FRIDAY 14 JANUARY 2021, 7.30 – IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), an OncoDNA group (…) »
16 July 2021
EVRY, FRANCE, FRIDAY 16 JULY 2021, 7.30AM – IntegraGen (FR0010908723 – ALINT (…) »
12 January 2021
IntegraGen announced today its unaudited business figures for the year 2020.
2020 revenue amounted to 9.0 M € versus 8.1 M € in 2019, an increase of 10% over 12 months. Increased sequencing services reported for company’s Evry lab and at outsourced platforms run by the company for the SeqOIA (…) »18 September 2020
IntegraGen has announced today its financial results for the first half of 2020 with the accounts having been reviewed by the Board of Directors on 17 September 2020.
Company posts positive operating performance (EBITDA) for the second consecutive semester, supported by revenue growth (+5%) and confirms (…) »